GlassScriptPhysician profile
Siddharth Bajpai
NPI 1093945727
$8,304.86
in general payments reported to CMS, 2019-2025
32 companies · $1,968 in 2025
The $1,968 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $239 · 2021: $183 · 2022: $1,195 · 2023: $1,906 · 2024: $1,594 · 2025: $1,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,429 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,428.85 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,061.84 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $735.77 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $661.94 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $655.90 | 2019-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $635.01 | 2021-2025 | Vraylar |
| Lundbeck LLC | $615.76 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $452.98 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $412.45 | 2022-2025 | Azstarys, Azstarys |
| Teva Pharmaceuticals USA, INC. | $355.58 | 2019-2024 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $343.87 | 2023-2025 | Auvelity |
| Alkermes, INC. | $315.42 | 2021-2025 | Aristada, Lybalvi |
| Bausch Health US, LLC | $295.88 | 2021-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $287.01 | 2022-2025 | Qelbree, Qelbree |
| Allergan, INC. | $240.14 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $235.89 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $171.52 | 2019-2023 | Ingrezza |
| Tris Pharma INC | $159.93 | 2019-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $104.82 | 2024-2025 | Cobenfy |
| Harmony Biosciences LLC | $87.37 | 2025 | |
| Avanir Pharmaceuticals, INC. | $78.78 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $52.88 | 2019-2024 | Relexxii |
| Jazz Pharmaceuticals INC. | $50.97 | 2020 | |
| Shire North American Group INC | $48.46 | 2019 | |
| Neos Therapeutics, LP | $39.25 | 2019-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $39.09 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $32.93 | 2020 | |
| Ironshore Pharmaceuticals INC. | $28.84 | 2019 | |
| Owp Pharmaceuticals, INC. | $25.75 | 2019 | |
| Sage Therapeutics, LLC | $22.23 | 2024 | |
| Idorsia Pharmaceuticals US INC | $21.75 | 2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $20.99 | 2025 | Lumryz |
| Aytu Biopharma, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siddharth Bajpai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.